Innovations in HER2-targeted therapy: A comprehensive review of trastuzumab deruxtecan

Key Points

• Trastuzumab deruxtecan shows enhanced efficacy against HER2-positive cancers and improved patient outcomes.
• Recent studies indicate a 60% overall response rate in patients treated with this therapy.
• This review summarizes evidence from multiple trials evaluating the effectiveness of trastuzumab deruxtecan against traditional methods.
• Advancements in targeted therapy may lead to more personalized treatments in HER2-positive cancer management.